ROCHE HLDG AG DIV RT (RHHVF)
-OTC Markets 263.38 23 May 01:05 SGT|Pre-Market
:
NaN
| Prev Close: | 263.38 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 154.90 - 263.38 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,735 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Xoma hires Genentech, Roche veteran as chief commercial officerat bizjournals.com(Tue, 19 Mar)
- Drug makers lobby states to restrict generic medicineat bizjournals.com(Fri, 1 Feb)
- $187.5 million Genentech licensing dealat bizjournals.com(Wed, 30 Jan)
- Heart disease test maker Singulex files for $86M IPOat bizjournals.com(Sat, 29 Sep)
- European panel recommends Avastin for type of ovarian cancer patientsat bizjournals.com(Sat, 22 Sep)
- ImmunoGen stock rises on lung cancer drug dataat bizjournals.com(Thu, 6 Sep)
- Daniel O'Day to lead Roche Pharma as Pascal Soriot moves to AstraZenecaat bizjournals.com(Tue, 28 Aug)
- Genentech seeks OK for 'armed antibody' to fight breast cancerat bizjournals.com(Mon, 27 Aug)
- Genentech seeks approval of 'armed antibody' targeting breast cancerat bizjournals.com(Mon, 27 Aug)
- Genentech's Lucentis approved for diabetic eye diseaseat bizjournals.com(Sat, 11 Aug)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Roche Holding Ltd operates in the fields of pharmaceuticals and diagnostics worldwide. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the early detection, ...
View More 
1.77%